MedPath

Clinical Trial News

Psychedelics Show Promise in Clinical Settings but Require Enhanced Safety Monitoring

  • A systematic review and meta-analysis of 114 studies indicates that classic psychedelics like LSD and psilocybin are generally well-tolerated in monitored clinical settings.
  • Serious adverse events were rare, with approximately 4% of participants with neuropsychiatric disorders experiencing SAEs, such as worsening depression or psychosis.
  • The study highlights significant gaps in adverse event reporting, emphasizing the need for improved pharmacovigilance practices to accurately assess risks and benefits.
  • Findings suggest a safer profile in clinical settings compared to recreational use, where catastrophic events like persistent psychotic disorders are more frequently reported.

Bioxcel Therapeutics Gains Analyst Confidence with Agitation Treatment Advancements

  • H.C. Wainwright reiterated a Buy rating for Bioxcel Therapeutics (BTAI), citing the Phase 3 trial of BXCL501 for agitation in bipolar disorder and schizophrenia.
  • The SERENITY At-Home trial's progress and potential for top-line results in H2 2025 could significantly increase the company's value.
  • Positive outcomes from the IGALMI post-marketing study, showing no tachyphylaxis, tolerance, or withdrawal, further support the Buy rating.
  • FDA's positive review of the SERENITY trial and planned submission of the TRANQUILITY trial for Alzheimer's agitation are viewed as positive steps.

Qualigen Therapeutics Announces Public Offering to Advance Cancer Programs

  • Qualigen Therapeutics is offering 14.7 million shares of common stock at $0.13 per share to fund operations and cancer drug development.
  • The offering includes pre-funded warrants for certain purchasers and aims to raise approximately $3.1 million after deducting fees.
  • Proceeds will support the clinical trial of QN-302 for pancreatic cancer and preclinical studies of the Pan-RAS program.
  • The offering's closing is expected by September 9, 2024, with Univest Securities, LLC acting as the exclusive placement agent.

FDA Meeting Highlights Urgent Need for Innovative PTSD Therapies, Including MDMA-Assisted Therapy

  • The FDA and Reagan-Udall Foundation convened a meeting to discuss advancing treatments for Post-Traumatic Stress Disorder (PTSD), highlighting the urgent need for innovative therapies.
  • Stakeholders, including individuals with PTSD and experts, voiced their support for MDMA-assisted therapy, despite the FDA's recent rejection of its application.
  • Experts emphasized MDMA-assisted therapy's potential to enhance neuroplasticity and allow patients to revisit traumatic experiences in a safe environment, fostering healing.
  • The meeting underscored the importance of addressing racial trauma and utilizing holistic tools to evaluate healing, particularly for communities of color.

Managing Toxicities in CLL Treatment: Expert Insights on BCL2 and BTK Inhibitor Selection

  • Leading experts at SOHO 2024 discuss critical strategies for managing toxicities in chronic lymphocytic leukemia patients treated with BCL2 and BTK inhibitors, emphasizing patient-specific approaches.
  • Renal function monitoring for BCL2 inhibitors and cardiovascular risk assessment for BTK inhibitors emerge as key considerations in treatment selection, with specific attention to comorbidities.
  • Novel treatment approaches including combination therapies, along with lifestyle interventions through programs like Health for CLL, are showing promise in improving patient outcomes and quality of life.

Collaborative Care Model Shows Strong Improvement in Depression and Anxiety Symptoms

  • A Kaiser Permanente study reveals that both collaborative care and traditional psychiatric treatment significantly improve depression and anxiety symptoms.
  • Collaborative care patients experienced a more substantial improvement, with depression symptoms decreasing by an average of 9 points.
  • A high proportion of depression patients in both programs achieved full remission, with 43% in collaborative care compared to 27% in specialty care.
  • The collaborative care model integrates frequent symptom monitoring, personalized treatment, and support from therapists and pharmacists.

Mivelsiran Shows Promise in Early Alzheimer's, BHV-7000 Enters Phase 2/3 for Focal Epilepsy

  • Early-stage data on mivelsiran, an RNA therapeutic, shows encouraging results for treating patients with early Alzheimer's disease.
  • Biohaven has initiated a phase 2/3 trial to evaluate BHV-7000, a potassium inhibitor, as a potential antiseizure medication for focal epilepsy.
  • Mirdametinib, an investigational treatment for neurofibromatosis type 1-associated plexiform neurofibromas, is being prioritized by SpringWorks Therapeutics.

Cell Therapy Shows Promise in Progressive Multiple Sclerosis

  • A cell therapy is under development for progressive multiple sclerosis (MS) patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.
  • GT201, a novel therapy, previously received IND clearance from China’s Center for Drug Evaluation in July 2023, marking a significant regulatory milestone.
  • Data from the pivotal part B cohort of the phase 2/3 DEVOTE clinical trial demonstrated an 85% median reduction in HS D2S6 levels in the CSF among patients receiving the pivotal dose.

Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 2b Trial

  • Cartesian Therapeutics' Descartes-08 met the primary endpoint in a Phase 2b trial for myasthenia gravis, demonstrating statistically significant improvement in MGC scores.
  • 71% of patients treated with Descartes-08 had clinically meaningful improvement in MGC score at Month 3, compared to 25% for placebo, highlighting its potential as a novel therapy.
  • The mRNA CAR-T therapy showed a favorable safety profile, supporting outpatient administration without the need for lymphodepleting chemotherapy, a significant advantage over traditional CAR-T therapies.
  • Updated Phase 2a results showed durable responses up to one year after retreatment, reinforcing Descartes-08's potential for long-term management of myasthenia gravis.

One-Year Trastuzumab Improves Disease-Free Survival in ERBB2-Positive Breast Cancer

  • A secondary analysis of the SOLD trial indicates that one year of adjuvant trastuzumab improves disease-free survival (DFS) compared to a 9-week regimen in patients with ERBB2-positive breast cancer.
  • The 5-year DFS rate was 90.7% in the 1-year trastuzumab group versus 87.7% in the 9-week group, highlighting a statistically significant benefit for the longer treatment duration.
  • The study suggests the 9-week regimen may be an option for patients who cannot tolerate or afford the one-year treatment, though overall survival rates were similar between both groups.
  • Longer follow-up revealed that factors such as positive axillary nodes, age, and disease stage were independently associated with the risk of death, but not the treatment duration.

The Synergism Or Long Duration (SOLD) Study

NCT00593697CompletedPhase 3
Finnish Breast Cancer Group
Posted 1/1/2008

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

NCT00629278Unknown StatusPhase 3
Azienda Ospedaliero-Universitaria di Modena
Posted 12/1/2007

Trending News

1

Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance One-Time Gene Editing Treatments for Cardiovascular Disease

3 days ago
2

Eli Lilly Acquires Gene-Editing Biotech Verve Therapeutics for $1.3 Billion to Expand Cholesterol Treatment Pipeline

3 days ago
3

AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint

4 days ago
4

NICE Rejects First Alzheimer's Disease-Modifying Drugs for NHS Use Due to Cost-Effectiveness Concerns

6 days ago
5

FDA Approves CSL's ANDEMBRY for Hereditary Angioedema Prevention with Novel Factor XIIa Targeting

4 days ago
6

Samsung Biologics Expands Into Preclinical Research with Launch of Samsung Organoids Drug Screening Platform

5 days ago
7

Johnson & Johnson's Dual-Targeting CAR-T Therapy Achieves 80% Complete Response Rate in Lymphoma Trial

7 days ago
8

FDA Approves Tafasitamab Triple Combination for Relapsed/Refractory Follicular Lymphoma

2 days ago
9

AbbVie's Atogepant Demonstrates Superior Tolerability and Efficacy Over Topiramate in Phase 3 Migraine Prevention Trial

2 days ago
10

Draig Therapeutics Emerges from Stealth with $140M to Advance Novel Neuropsychiatric Therapies

2 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy